KDR overexpression
|
GBM
|
KDR overexpression
|
GBM
|
bevacizumab + erlotinib Resistant: C3 – Early Trials
|
bevacizumab + erlotinib Resistant: C3 – Early Trials
|
KDR overexpression
|
HCC
|
KDR overexpression
|
HCC
|
bevacizumab + atezolizumab Sensitive: C3 – Early Trials
|
bevacizumab + atezolizumab Sensitive: C3 – Early Trials
|
KDR overexpression
|
GBM
|
KDR overexpression
|
GBM
|
bevacizumab Resistant: C3 – Early Trials
|
bevacizumab Resistant: C3 – Early Trials
|
KDR overexpression
|
Breast Cancer
|
KDR overexpression
|
Breast Cancer
|
sunitinib Sensitive: C4 – Case Studies
|
sunitinib Sensitive: C4 – Case Studies
|